Sexually Transmitted Diseases, Viral News

Sexually Transmitted Diseases, Viral	Welcome, Profile Billing Logout

«1 2...38 39 40 41 42 43 44 45 46 47 484950 »

||||||||||  efavirenz / Generic mfg., fosamprenavir / Generic mfg.
Trial completion:  A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT (clinicaltrials.gov) -  Oct 13, 2011
P3, N=101, Completed,  Sponsor: Georgetown University
Active, not recruiting --> Completed

||||||||||  methamphetamine / Generic mfg.
Enrollment change:  Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men (clinicaltrials.gov) -  Oct 12, 2011
P2, N=53, Completed,  Sponsor: Friends Research Institute, Inc.
Active, not recruiting --> Completed N=40 --> 53

||||||||||  efavirenz / Generic mfg., lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion:  LYNX: A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine (clinicaltrials.gov) -  Oct 12, 2011
P=N/A, N=346, Completed,  Sponsor: AbbVie (prior sponsor, Abbott)
N=40 --> 53 Recruiting --> Completed

||||||||||  efavirenz / Generic mfg.
New P3 trial:  ENCORE1-CNS;NCHECR-ENCORE1-CNS: The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1 (clinicaltrials.gov) -  Oct 11, 2011
P3, N=32, Completed,  Sponsor: Kirby Institute

||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
New P3 trial, Combination therapy:  FLAMINGO: Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects (clinicaltrials.gov) -  Oct 6, 2011
P3, N=488, Active, not recruiting,  Sponsor: ViiV Healthcare

||||||||||  Selzentry (maraviroc) / ViiV Healthcare
New P4 trial:  A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac) (clinicaltrials.gov) -  Oct 5, 2011
P4, N=140, Not yet recruiting,  Sponsor: Bruce Brew

||||||||||  Isentress (raltegravir) / Merck (MSD)
New P4 trial:  HANDral: A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV (clinicaltrials.gov) -  Oct 5, 2011
P4, N=6, Terminated,  Sponsor: St Vincent's Hospital, Sydney

||||||||||  darunavir/ritonavir / Generic mfg.
New P3 trial, Combination therapy, Monotherapy:  A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment (clinicaltrials.gov) -  Oct 5, 2011
P3, N=274, Active, not recruiting,  Sponsor: Janssen-Cilag International NV

|||||||||| Trial completion: Botswana Diarrheal Diseases Study (clinicaltrials.gov) - Oct 5, 2011
P=N/A, N=1350, Completed, Sponsor: Harvard School of Public Health
Recruiting --> Completed Recruiting --> Completed

|||||||||| Enrollment change: Lactate Metabolism Study in HIV Infected Persons (clinicaltrials.gov) - Oct 4, 2011
P4, N=30, Completed, Sponsor: Queen's University
Recruiting --> Completed N=40 --> 30

|||||||||| Trial completion: Lactate Metabolism Study in HIV Infected Persons (clinicaltrials.gov) - Oct 4, 2011
P4, N=30, Completed, Sponsor: Queen's University
N=40 --> 30 Active, not recruiting --> Completed

||||||||||  lovastatin / Generic mfg.
Trial completion, IO biomarker, Immunomodulating:  LIVE: Lovastatin: Immunomodulatory Value Evaluation (clinicaltrials.gov) -  Sep 27, 2011
P2, N=112, Completed,  Sponsor: Universidad de Antioquia
Active, not recruiting --> Completed Enrolling by invitation --> Completed

||||||||||  Isentress (raltegravir) / Merck (MSD)
Trial termination:  RAG-1/2: Immune Responses in Patients Treated With Raltegravir (clinicaltrials.gov) -  Sep 26, 2011
P3, N=0, Terminated,  Sponsor: McGill University Health Center
Enrolling by invitation --> Completed Active, not recruiting --> Terminated; Unexpected and severe difficulties in recruitment.

||||||||||  Isentress (raltegravir) / Merck (MSD)
Enrollment change:  RAG-1/2: Immune Responses in Patients Treated With Raltegravir (clinicaltrials.gov) -  Sep 26, 2011
P3, N=0, Terminated,  Sponsor: McGill University Health Center
Active, not recruiting --> Terminated; Unexpected and severe difficulties in recruitment. N=60 --> 0

||||||||||  atorvastatin / Generic mfg.
New P2/3 trial:  Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial (clinicaltrials.gov) -  Sep 26, 2011
P2/3, N=0, Withdrawn,  Sponsor: University of Minnesota - Clinical and Translational Science Institute

||||||||||  Isentress (raltegravir) / Merck (MSD)
Trial completion, Discordant:  Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product (clinicaltrials.gov) -  Sep 26, 2011
P4, N=57, Completed,  Sponsor: Germans Trias i Pujol Hospital
N=60 --> 0 Active, not recruiting --> Completed

|||||||||| Enrollment change: Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients (clinicaltrials.gov) - Sep 25, 2011
P1, N=33, Active, not recruiting, Sponsor: Sangamo Biosciences
Active, not recruiting --> Completed N=18 --> 33

|||||||||| New P1 trial: A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002) (clinicaltrials.gov) - Sep 25, 2011
P1, N=11, Terminated, Sponsor: Istituto Superiore di Sanita

||||||||||  Tybost (cobicistat) / Gilead
New P3 trial:  Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults (clinicaltrials.gov) -  Sep 22, 2011
P3, N=300, Active, not recruiting,  Sponsor: Gilead Sciences

|||||||||| New P2 trial: Safer Sex Program for Young African-American Men (clinicaltrials.gov) - Sep 21, 2011
P2, N=620, Recruiting, Sponsor: University of Kentucky

||||||||||  atorvastatin / Generic mfg.
Enrollment change:  Modulation of Monocyte Activation by Atorvastatin in HIV Infection (clinicaltrials.gov) -  Sep 20, 2011
P4, N=15, Active, not recruiting,  Sponsor: University of Pennsylvania
N=18 --> 33 N=20 --> 15

||||||||||  nevirapine / Generic mfg.
Trial completion:  PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice. (clinicaltrials.gov) -  Sep 20, 2011
P=N/A, N=280, Completed,  Sponsor: Boehringer Ingelheim
N=20 --> 15 Recruiting --> Completed

||||||||||  Fuzeon (enfuvirtide) / Roche
Trial completion:  INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. (clinicaltrials.gov) -  Sep 18, 2011
P2, N=29, Completed,  Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed

|||||||||| New P2 trial, PD(L)-1 Biomarker, IO biomarker: The Effect of Probiotics in HIV-1 Infection (clinicaltrials.gov) - Sep 15, 2011
P2, N=100, Recruiting, Sponsor: Oslo University Hospital

||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
Trial completion:  Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir (clinicaltrials.gov) -  Sep 15, 2011
P1, N=20, Completed,  Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Enrollment change: CHAI: Role of Positive Affect in Adjustment to HIV (clinicaltrials.gov) - Sep 14, 2011
P=N/A, N=160, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=300 --> 160

|||||||||| Trial completion: CHAI: Role of Positive Affect in Adjustment to HIV (clinicaltrials.gov) - Sep 14, 2011
P=N/A, N=160, Completed, Sponsor: University of California, San Francisco
N=300 --> 160 Active, not recruiting --> Completed

|||||||||| Trial termination: Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults (clinicaltrials.gov) - Sep 13, 2011
P1, N=3, Terminated, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Active, not recruiting --> Terminated

|||||||||| Trial completion: A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C (clinicaltrials.gov) - Sep 13, 2011
P1/2, N=40, Completed, Sponsor: Henry Sacks
Active, not recruiting --> Terminated Active, not recruiting --> Completed

|||||||||| Enrollment open: Evaluating Methods to Increase HIV Testing, Access to HIV Care, and HIV Prevention Strategies (clinicaltrials.gov) - Sep 12, 2011
P=N/A, N=22000, Recruiting, Sponsor: HIV Prevention Trials Network
Active, not recruiting --> Completed Active, not recruiting --> Recruiting

|||||||||| Trial completion: Vitamin D Dose Finding Study (clinicaltrials.gov) - Sep 12, 2011
P2, N=44, Completed, Sponsor: Children's Hospital of Philadelphia
Active, not recruiting --> Recruiting Recruiting --> Completed

|||||||||| Trial completion: C001: Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults (clinicaltrials.gov) - Sep 11, 2011
P1, N=45, Completed, Sponsor: International AIDS Vaccine Initiative
Recruiting --> Completed No longer recruiting --> Completed

|||||||||| Trial completion, Adherence: An Expanded Safety Study of Dapivirine Gel 4759 in Africa (clinicaltrials.gov) - Sep 8, 2011
P1/2, N=280, Completed, Sponsor: International Partnership for Microbicides, Inc.
No longer recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Selzentry (maraviroc) / ViiV Healthcare
Trial withdrawal:  A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium (clinicaltrials.gov) -  Sep 7, 2011
P1, N=0, Withdrawn,  Sponsor: International Partnership for Microbicides, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn

||||||||||  Selzentry (maraviroc) / ViiV Healthcare
Enrollment change:  A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium (clinicaltrials.gov) -  Sep 7, 2011
P1, N=0, Withdrawn,  Sponsor: International Partnership for Microbicides, Inc.
Not yet recruiting --> Withdrawn N=40 --> 0

|||||||||| Trial completion, Enrollment change: Study of Tests to Evaluate Effectiveness of Anti-HIV Drugs (clinicaltrials.gov) - Sep 6, 2011
P=N/A, N=14, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=40 --> 0 N=100 --> 14 | Recruiting --> Completed

|||||||||| Trial completion: Study of Tests to Evaluate Effectiveness of Anti-HIV Drugs (clinicaltrials.gov) - Sep 6, 2011
P=N/A, N=14, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=100 --> 14 | Recruiting --> Completed Recruiting --> Completed

|||||||||| Enrollment change: Life Skills Intervention for Adolescents Perinatally Infected With HIV (clinicaltrials.gov) - Sep 5, 2011
P=N/A, N=16, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Completed N=40 --> 16

|||||||||| Enrollment change: Metabolic Abnormalities in HIV Infected and Uninfected Young Women (clinicaltrials.gov) - Sep 5, 2011
P=N/A, N=300, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
N=40 --> 16 N=250 --> 300

|||||||||| Trial completion: Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women (clinicaltrials.gov) - Sep 5, 2011
P2, N=99, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
N=250 --> 300 Active, not recruiting --> Completed

|||||||||| Trial completion: C2P Mobilization Intervention (Pilot) (clinicaltrials.gov) - Sep 5, 2011
P3, N=15, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Completed Recruiting --> Completed

|||||||||| Trial completion: C2P - Phase III: MPowerment and Community Promise (clinicaltrials.gov) - Sep 5, 2011
P3, N=15, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Completed Recruiting --> Completed

||||||||||  Selzentry (maraviroc) / ViiV Healthcare
Clinical:  Safety Study of Maraviroc's Effect on Human Osteoclasts (clinicaltrials.gov) -  Sep 1, 2011
P=N/A, N=20, Enrolling by invitation,  Sponsor: National Center for Global Health and Medicine, Japan

|||||||||| Trial completion: A Trial of Vitamins and HAART in HIV Disease Progression (clinicaltrials.gov) - Sep 1, 2011
P3, N=4012, Completed, Sponsor: Harvard School of Public Health
Recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial withdrawal: Effectiveness of the Diaphragm for HIV Prevention (clinicaltrials.gov) - Aug 31, 2011
P3, N=5000, Withdrawn, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Withdrawn

||||||||||  Stamaril (yellow fever vaccine) / Sanofi
New P3 trial:  The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. (clinicaltrials.gov) -  Aug 29, 2011
P3, N=71, Active, not recruiting,  Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

|||||||||| Trial completion: Bone Mineral Density (BMD) in HIV Infection (clinicaltrials.gov) - Aug 28, 2011
P=N/A, N=0, Completed, Sponsor: University Hospital, Strasbourg, France
Active, not recruiting --> Withdrawn Active, not recruiting --> Completed

|||||||||| Trial termination: Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023) (clinicaltrials.gov) - Aug 25, 2011
P2, N=3000, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Completed --> Terminated

||||||||||  Pegasys (pegylated interferon ? -2a) / Roche
Trial completion:  Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection (clinicaltrials.gov) -  Aug 24, 2011
P2, N=23, Completed,  Sponsor: University of Pennsylvania
Completed --> Terminated Active, not recruiting --> Completed

||||||||||  emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion, Adherence:  A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa (clinicaltrials.gov) -  Aug 23, 2011
P1/2, N=72, Completed,  Sponsor: International AIDS Vaccine Initiative
Active, not recruiting --> Completed Active, not recruiting --> Completed



	Diseases Companies Products Productz Mechanisms of Action Sites